| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052254 | The Journal of Urology | 2005 | 5 Pages |
Abstract
Men with high risk but nonmetastatic prostate cancer are more likely to receive radiation therapy as well as androgen deprivation with the latter as primary therapy or in conjunction with local treatment. These data stress the importance of pretreatment risk stratification, education regarding appropriate combinations of local and systemic therapies, and the consideration of novel clinical trials in patients at higher risk.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
MAXWELL V. MENG, ERIC P. ELKIN, DAVID M. LATINI, JANEEN DuCHANE, PETER R. CARROLL,